1. Home
  2. ELVN vs EWTX Comparison

ELVN vs EWTX Comparison

Compare ELVN & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enliven Therapeutics Inc.

ELVN

Enliven Therapeutics Inc.

N/A

Current Price

$46.48

Market Cap

4.2B

Sector

Health Care

ML Signal

N/A

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

N/A

Current Price

$39.87

Market Cap

4.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ELVN
EWTX
Founded
2016
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.3B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
ELVN
EWTX
Price
$46.48
$39.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
13
Target Price
★ $74.33
$56.17
AVG Volume (30 Days)
1.2M
★ 1.4M
Earning Date
11-05-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 3.17
N/A
EPS
N/A
★ 8.86
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$4.65
Revenue Growth
N/A
N/A
52 Week Low
$14.79
$19.76
52 Week High
$62.32
$48.78

Technical Indicators

Market Signals
Indicator
ELVN
EWTX
Relative Strength Index (RSI) 49.64 44.25
Support Level $44.18 $37.22
Resistance Level $46.96 $41.60
Average True Range (ATR) 2.47 3.20
MACD -0.17 -0.37
Stochastic Oscillator 25.69 26.45

Price Performance

Historical Comparison
ELVN
EWTX

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Share on Social Networks: